Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company dedicated to developing light and/or radiation activated small molecules for effectively destroying cancers, bacteria, and viruses. Their lead compound, RuvidarTM, has shown promise in inactivating various viruses and increasing efficacy in cancer cell destruction. Recent research has demonstrated RuvidarTM's ability to reverse the charge of BCG, creating a compound, RuBCG, with enhanced cancer cell kill rates. Additionally, Rutherrin® has proven effective in increasing chemotherapy efficacy and reducing multidrug resistance in cancer cells. Theralase is committed to advancing innovative therapies to combat challenging diseases and improve patient outcomes.
Theralase Technologies, a clinical stage pharmaceutical company, has successfully closed the first tranche of its Non-Brokered Private Placement (NBPP) offering. The company raised $CAN 775,000 by issuing 3,522,729 units at $CAN 0.22 per unit. Each unit includes one common share and one common share purchase warrant, allowing holders to acquire additional shares at $CAN 0.30 each for five years. Funds will support the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, preclinical research of Rutherrin®, and general corporate purposes. The securities are under a four-month hold and await final acceptance from the TSX Venture Exchange.
Theralase Technologies announced that its lead drug, Rutherrin, has shown promise in repurposing non-cancer drugs for cancer therapy in preclinical research. Rutherrin enhances the efficacy of existing drugs, such as Withaferin A, Amiodarone, and Metformin, in destroying cancer cells. This approach leverages already approved drugs, potentially reducing development costs and timelines. Dr. Arkady Mandel, the Chief Scientific Officer, highlighted the shared molecular pathways between different diseases as a rationale for this repurposing strategy. President Roger DuMoulin-White emphasized the high costs and long timelines of new drug development, underscoring the benefits of repurposing existing drugs for cancer treatment.
Theralase Technologies announced that its lead drug formulation, Rutherrin®, demonstrated a complete response in preclinical studies for Non-Small Cell Lung Cancer (NSCLC). Using a well-established Lewis Lung Cancer (LLC1) model, mice treated with x-ray activated Rutherrin® showed a significant reduction in tumor progression and increased overall survival compared to the control group treated with radiation only. Notably, one mouse achieved a complete response, becoming cancer-free. The company aims to optimize this therapy for higher success rates and expand its cancer treatment targets, which now include bladder, brain, lung, and various blood-based cancers. Pending further research and sufficient funding, Theralase plans to commence clinical studies for these cancers.
Theralase Technologies announced preclinical research revealing that their lead drug, Rutherrin, enhances the efficacy of immunotherapy for cancer treatment. Rutherrin works by killing cancer cells directly and reducing the expression of PD-L1 checkpoint proteins, thus increasing the effectiveness of immunotherapeutic drugs. This combined approach potentially reduces the number of treatments needed and associated side effects. The research was conducted on Non-Muscle Invasive Bladder Cancer (NMIBC) and Glioblastoma Multiforme (GBM) cells, showing significant PD-L1 expression reduction. Additionally, Rutherrin combined with x-ray radiation increased calreticulin expression, an immune system activator, suggesting higher cancer cell destruction rates. Theralase aims to leverage these findings for better cancer treatment outcomes.
Theralase has announced a reminder notice for its Annual General and Special Meeting (AGSM) on June 19, 2024, at 4:30 pm ET, located at 41 Hollinger Road, Toronto, Ontario. The company, focusing on light and radiation-activated therapies for cancer, bacteria, and viruses, will also host a virtual Zoom presentation from 5:30 to 6:30 pm ET, including a corporate presentation and a Q&A session. Shareholders can join via Zoom or conference call, with the session archived on the company's website.
Theralase Technologies has announced promising preclinical results for its lead drug, Rutherrin, which increases the efficacy of chemotherapy while combating multidrug resistance (MDR) in cancer cells. MDR often limits the effectiveness of cancer treatments as cancer cells expel drugs before they can be effective. Rutherrin inhibits this drug expulsion, leading to higher drug retention and increased cancer cell kill rates. The research used various chemotherapeutic drugs and demonstrated significant improvements in drug retention and cancer cell mortality in vitro and in animal models. These findings suggest Rutherrin could significantly enhance current cancer treatments by overcoming MDR, reducing adverse effects, and improving patient outcomes.
Theralase Technologies has announced promising preclinical results for its lead compound, RuvidarTM, when combined with Bacillus Calmette-Guérin (BCG) to form RuBCG. The new compound significantly enhances the efficacy of BCG in killing bladder cancer cells by reversing the negative charge of BCG, allowing better adhesion to cancer cells. In experiments, RuBCG increased cancer cell kill rates and decreased immune checkpoint inhibitor PD-L1 levels. The results suggest RuBCG could offer a more effective treatment for Non-Muscle Invasive Bladder Cancer (NMIBC), potentially overcoming the limitations of BCG alone.
Theralase Technologies announced that its lead compound, Ruvidar, combined with transferrin to form Rutherrin, has shown preclinical effectiveness in destroying Non-Small Cell Lung Cancer (NSCLC). Experiments using a Lewis Lung Cancer model demonstrated that Rutherrin stays longer in tumor tissues than in normal lung tissues, leading to enhanced selectivity. All mice treated with x-ray activated Rutherrin survived, showing up to a 4-fold slower tumor progression compared to those treated with radiation alone. Theralase plans to start a Phase Ia clinical study for GBM and NSCLC in Q4 2024, with possible expansions into other cancers like pancreatic, prostate, kidney, and colorectal cancers, pending successful GLP toxicology results and capitalization.
Theralase Technologies announced that its lead compound, RuvidarTM, has proven effective in inactivating various viruses, including enveloped and non-enveloped ones. Research conducted at the University of Manitoba and the National Microbiology Laboratory demonstrated RuvidarTM's potency, showing effectiveness at concentrations 100 times lower than previously tested antiviral compounds. The findings, published in Heliyon, suggest that RuvidarTM could be a broad-spectrum viral vaccine candidate, particularly effective against viruses such as H1N1 influenza, coronavirus, Zika, and herpes. Theralase plans to focus on developing RuvidarTM for commercial use, including a topical therapeutic for herpes lesions. The company's shift in research focus towards developing an avian influenza vaccine has also gained consensus from the National Microbiology Laboratory.
Theralase Technologies, a clinical-stage pharmaceutical company, released its unaudited interim consolidated 1Q2024 financial statements. Key highlights include a 15% YoY revenue decline, with a gross margin of $62,114, down from $92,523 in 2023. Costs and expenses saw varied changes, with a notable 20% decrease in Drug Division R&D expenses to $725,017 and an 886% increase in Device Division R&D expenses to $31,363. Net loss reduced by 10% to $1,266,711.
Operationally, Theralase closed a $750,200 private placement and made significant progress in Study II, treating 68 patients, with a 63% complete response rate. Key updates on clinical data and Break Through Designation (BTD) submission to the FDA were also shared. The company aims for full patient enrollment in Study II by 2024 end, data lock by mid-2026, and FDA/Health Canada approval by late 2026.
FAQ
What is Theralase Technologies Inc. focused on?
What is RuvidarTM and its significance?
How does RuvidarTM impact BCG in cancer treatment?
What is the role of Rutherrin® in chemotherapy?